Preferred Label : agomelatine;

MeSH note : RN from Toxlit; an antidepressant;

CISMeF synonym : AGO 178; S20098;

MeSH synonym : N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide;

MeSH hyponym : AGO178; AGO-178; S 20098; S-20098;

MeSH Related Number : 138112-76-2;

Registry Number MeSH : 138112-76-2;

Is substance : O;

UNII : 137R1N49AD;

Details


Main resources

You can consult :


https://www.cochrane.org/fr/CD011271/melatonine-et-agomelatine-pour-la-prevention-de-la-depression-hivernale
2019
false
true
false
false
France
United Kingdom
melatonin
agomelatine
seasonal affective disorder
treatment outcome
adult
review of literature
french abstract
agomelatine
acetamides

---
https://ansm.sante.fr/tableau-marr/agomelatine
2018
false
false
false
France
French
depressive disorder, major
patients guideline
guidelines for drug use
continuity of patient care
drug monitoring
drug interactions
cytochrome p-450 cyp1a2
agomelatine
agomelatine
antidepressive agents
antidepressive agents
agomelatine
liver function tests
risk management
Chemical and Drug Induced Liver Injury
risk factors
transaminases
administration, oral
agomelatine
agomelatine
acetamides
acetamides

---
http://www.has-sante.fr/portail/jcms/c_2572142/fr/valdoxan
http://www.has-sante.fr/portail/jcms/c_2572142/fr/valdoxan-agomelatine-antidepresseur
2015
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
agomelatine
acetamides
melatonin
antidepressive agents
agomelatine
depressive disorder, major
treatment outcome
administration, oral
receptor, serotonin, 5-ht2c
adult
serotonin 5-HT2 receptor antagonists

---
https://www.ema.europa.eu/medicines/human/EPAR/Valdoxan
2012
United Kingdom
French
English
syndication feed
depressive disorder, major
tablets
agomelatine
agomelatine
administration, oral
treatment outcome
drug evaluation
antidepressive agents
antidepressive agents
melatonin
receptor, serotonin, 5-ht2c
receptor, melatonin, mt1
receptor, melatonin, mt2
acetamides
acetamides
adult
drug interactions
pregnancy
breast feeding
agomelatine
serotonin 5-HT2 receptor antagonists
serotonin 5-HT2 receptor antagonists
acetamides
drug evaluation
summary of product characteristics
package leaflet

---
https://www.ema.europa.eu/medicines/human/EPAR/Thymanax
2012
United Kingdom
English
French
syndication feed
tablets
administration, oral
depressive disorder, major
adult
treatment outcome
drug evaluation
agomelatine
agomelatine
melatonin
acetamides
acetamides
drug interactions
agomelatine
pregnancy
breast feeding
antidepressive agents
antidepressive agents
receptor, melatonin, mt1
receptor, melatonin, mt2
receptor, serotonin, 5-ht2c
drug evaluation, preclinical
acetamides
serotonin 5-HT2 receptor antagonists
serotonin 5-HT2 receptor antagonists
drug evaluation
summary of product characteristics
package leaflet

---
http://www.has-sante.fr/portail/jcms/c_929446/quelle-place-pour-lagomelatine-valdoxan-dans-le-traitement-de-la-depression
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/fiche_bum_valdoxan.pdf
2010
France
French
agomelatine
acetamides
melatonin
antidepressive agents
agomelatine
depressive disorder, major
continuity of patient care
treatment outcome
administration, oral
receptor, serotonin, 5-ht2c
adult
serotonin 5-HT2 receptor antagonists
acetamides
guidelines for drug use

---
http://www.has-sante.fr/portail/jcms/c_923729/valdoxan-agomelatine-antidepresseur
http://www.has-sante.fr/portail/jcms/c_900492/valdoxan
2009
false
false
Haute Autorité de santé
France
French
agomelatine
agomelatine
acetamides
melatonin
receptor, serotonin, 5-ht2c
adult
depressive disorder, major
antidepressive agents
insurance, health, reimbursement
aged
treatment outcome
continuity of patient care
drug monitoring
administration, oral
agomelatine
acetamides
antidepressive agents
serotonin 5-HT2 receptor antagonists
acetamides
guidelines for drug use
evaluation of the transparency committee

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.